According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company’s product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. “
Several other research analysts have also recently weighed in on ARDS. Laidlaw set a $15.00 target price on Aridis Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, September 4th. Northland Securities restated a buy rating and set a $22.00 target price on shares of Aridis Pharmaceuticals in a report on Thursday, November 14th. ValuEngine upgraded Aridis Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, Maxim Group set a $25.00 target price on Aridis Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $19.80.
Aridis Pharmaceuticals (NASDAQ:ARDS) last issued its earnings results on Wednesday, November 13th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.54). Aridis Pharmaceuticals had a negative return on equity of 182.31% and a negative net margin of 660.52%. As a group, sell-side analysts predict that Aridis Pharmaceuticals will post -3.79 earnings per share for the current fiscal year.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Featured Article: Quick Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.